Second quarter results met expectations with strong volume growth from improved mortality, offset by lower commercial mix and phosphate binder revenue. Full-year guidance is reaffirmed, with continued investment in clinical innovation and capital allocation discipline.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.